Dacarbazine
drugOn this page
Also known as Biocarbazine rDacarbasineDacarbazinaDacarbazinumDecarbazineDICDicarbazineDTICDtic-domeNCI C04717NSC-45388SID17389952SID26747399SID99125
Summary
Dacarbazine (CHEMBL476) is an approved small molecule (ATC L01AX04); indicated across 25 conditions including metastatic melanoma and melanoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: L01AX04
- Indications: 25 conditions
- Clinical trials: 168
- Chemistry: 182.18 Da · C6H10N6O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL476 |
| Name | Dacarbazine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 135398738 |
| ChEBI | CHEBI:177836 |
| ATC | L01AX04 |
| Molecular formula | C6H10N6O |
| Molecular weight | 182.18 |
| InChIKey | FDKXTQMXEQVLRF-ZHACJKMWSA-N |
SMILES: CN(C)/N=N/C1=C(NC=N1)C(=O)N
IUPAC name: 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
ChEBI definition: A dacarbazine in which the N=N double bond adopts a trans-configuration.
Also known as: Biocarbazine r, Dacarbasine, Dacarbazina, Dacarbazine, Dacarbazinum, Decarbazine, DIC, Dicarbazine, DTIC, Dtic-dome, NCI C04717, NSC-45388
Patent coverage: 32,751 distinct patent families (132,965 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 132,830 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, Inositol monophosphatase 1, Thyrotropin receptor, Matrix metalloproteinase-9, Aldehyde dehydrogenase 1A1.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| MMP9 | 6.25 | IC50 | 556 | nM | CHEMBL_ACT_7702256 |
| SMN1 | 5.2 | Potency | 6310 | nM | CHEMBL_ACT_3886039 |
| P97697 | 5.2 | Potency | 6310 | nM | CHEMBL_ACT_4405624 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
25 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| metastatic melanoma | 4 | MONDO:0005191 | EFO:0002617 |
| melanoma | 4 | MONDO:0005105 | EFO:0000756 |
| cutaneous melanoma | 4 | MONDO:0005012 | EFO:0000389 |
| Hodgkins lymphoma | 4 | MONDO:0004952 | EFO:0000183 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| sarcoma | 3 | MONDO:0005089 | EFO:0000691 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| neuroblastoma | 3 | MONDO:0005072 | EFO:0000621 |
| soft tissue sarcoma | 3 | MONDO:0018078 | EFO:1001968 |
| peripheral T-cell lymphoma, not otherwise specified | 3 | MONDO:0004964 | EFO:0000211 |
| leiomyosarcoma | 3 | MONDO:0005058 | EFO:0000564 |
| synovial sarcoma | 3 | MONDO:0010434 | EFO:0001376 |
| alveolar soft part sarcoma | 3 | MONDO:0011655 | EFO:0007143 |
| skin neoplasm | 3 | MONDO:0002531 | MONDO:0002898 |
| uveal melanoma | 3 | MONDO:0006486 | EFO:1000616 |
| pancreatic neuroendocrine tumor | 2 | MONDO:0019954 | EFO:1000045 |
| neuroendocrine neoplasm | 2 | MONDO:0019496 | EFO:1001901 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| lung neoplasm | 1 | MONDO:0021117 | MONDO:0008903 |
| colonic neoplasm | 1 | MONDO:0005401 | EFO:0004288 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 168.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 83 |
| PHASE3 | 53 |
| PHASE1/PHASE2 | 13 |
| PHASE1 | 9 |
| Not specified | 6 |
| PHASE2/PHASE3 | 3 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06831370 | PHASE4 | RECRUITING | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India |
| NCT02661503 | PHASE3 | ACTIVE_NOT_RECRUITING | HD21 for Advanced Stages |
| NCT03016819 | PHASE3 | RECRUITING | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) |
| NCT03907488 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
| NCT04221035 | PHASE3 | RECRUITING | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
| NCT04638790 | PHASE3 | RECRUITING | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) |
| NCT04685616 | PHASE3 | RECRUITING | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma |
| NCT05675410 | PHASE3 | RECRUITING | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab |
| NCT05987332 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| NCT06346067 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) |
| NCT06563245 | PHASE2/PHASE3 | RECRUITING | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment |
| NCT06743126 | PHASE3 | RECRUITING | SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
| NCT00002561 | PHASE3 | COMPLETED | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin’s Disease |
| NCT00002802 | PHASE3 | COMPLETED | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma |
| NCT00002882 | PHASE3 | COMPLETED | Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma |
| NCT00003027 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma |
| NCT00003389 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin’s Lymphoma |
| NCT00003421 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Advanced Hodgkin’s Disease |
| NCT00003647 | PHASE3 | COMPLETED | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma |
| NCT00005090 | PHASE3 | TERMINATED | S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin’s Disease |
| NCT00006237 | PHASE3 | COMPLETED | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma |
| NCT00016263 | PHASE3 | COMPLETED | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma |
| NCT00038558 | PHASE3 | COMPLETED | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy |
| NCT00041210 | PHASE3 | UNKNOWN | Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin’s Lymphoma |
| NCT00049595 | PHASE3 | COMPLETED | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin’s Lymphoma |
| NCT00072124 | PHASE3 | COMPLETED | Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma |
| NCT00087776 | PHASE3 | TERMINATED | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma |
| NCT00091572 | PHASE3 | COMPLETED | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) |
| NCT00257205 | PHASE3 | COMPLETED | CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy |
| NCT00264953 | PHASE3 | COMPLETED | HD11 for Intermediate Stages |
| NCT00265018 | PHASE3 | COMPLETED | HD10 for Early Stages |
| NCT00324155 | PHASE3 | COMPLETED | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma |
| NCT00395070 | PHASE3 | COMPLETED | A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma |
| NCT00410631 | PHASE3 | UNKNOWN | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma |
| NCT00433459 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Hodgkin’s Lymphoma |
| NCT00678327 | PHASE3 | COMPLETED | Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma |
| NCT00779714 | PHASE3 | UNKNOWN | Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC |
| NCT00864253 | PHASE3 | COMPLETED | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma |
| NCT00920153 | PHASE3 | TERMINATED | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma |
| NCT01006980 | PHASE3 | COMPLETED | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).